A new membership program, SmartRx, offers consumers savings on prescriptions, as well as office visits, eye care, vaccines and pet meds.
A new prescription discount card, SmartRx, a division of Smarty, joins GoodRx and SingleCare in the prescription discount card arena. SmartRx offers its users a free discount card and a paid membership program. The SmartRx Discount Card helps consumers save up to 80% on their prescription drugs. SmartRx+ is a monthly membership program that offers rebates for doctor or dentist visits, telehealth care, prescription glasses or contacts, annual vaccines, and pet medications.
Vipin Porwal
“An increase in healthcare costs over the past few years coupled with this past year’s inflation rates have really affected consumer’s bottom line. SmartRx is a smart healthcare cost saving solution that goes beyond prescription drug costs to help tackle these consumer concerns about health care costs,” Vipin Porwal, chief executive officer and founder of Smarty and SmartRx, told Formulary Watch.
SmartRx works with PBMs to pass on discounts when consumers present their SmartRx coupon or discount card at the pharmacy, Porwal said.
The membership rate for SmartyRx+ is $19 per month after a seven-day trial for $3. Users get a $15 cashback bonus rebate on their first prescription purchase, plus $30 annual rebate for vaccines, $50 a month for doctor and dental visits, $125 for annual for prescription glasses and contacts, $25 a month for pet medications, and other rebates.
In addition, the SmartRx Discount Card is accepted at more than 65,000 pharmacies nationwide.
In a recent SmartRx survey, 66% of respondents agreed or strongly agreed that prescriptions are too costly. Nearly half (48%) of respondents said they would use a subscription service that offers cashback and rebates on prescriptions.
Smarty is an online shopping destination that automatically applies the best coupon on purchases from more than 6,000 U.S. retailers and 1,500 global merchants.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More